Cantel Medical Corp. (NYSE:CMD) was the recipient of a large decline in short interest during the month of October. As of October 13th, there was short interest totalling 798,587 shares, a decline of 32.0% from the September 29th total of 1,175,114 shares. Based on an average daily volume of 222,726 shares, the short-interest ratio is currently 3.6 days.

In related news, Chairman Charles M. Diker sold 20,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $99.15, for a total value of $2,032,575.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eric W. Nodiff sold 2,868 shares of the business’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $97.55, for a total transaction of $279,773.40. Following the completion of the transaction, the executive vice president now owns 39,102 shares of the company’s stock, valued at approximately $3,814,400.10. The disclosure for this sale can be found here. Insiders sold a total of 36,368 shares of company stock valued at $3,576,028 in the last 90 days. 14.90% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in CMD. Capstone Asset Management Co. bought a new position in shares of Cantel Medical Corp. during the second quarter valued at $690,000. Bank of Montreal Can bought a new position in shares of Cantel Medical Corp. during the second quarter valued at $248,000. GW&K Investment Management LLC bought a new position in shares of Cantel Medical Corp. during the second quarter valued at $30,121,000. Pennsylvania Trust Co bought a new position in shares of Cantel Medical Corp. during the second quarter valued at $6,590,000. Finally, State of Alaska Department of Revenue bought a new position in shares of Cantel Medical Corp. during the second quarter valued at $558,000. 83.82% of the stock is owned by hedge funds and other institutional investors.

Several research analysts recently weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Cantel Medical Corp. in a research report on Friday, September 1st. Zacks Investment Research upgraded shares of Cantel Medical Corp. from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, Sidoti upgraded shares of Cantel Medical Corp. from a “neutral” rating to a “buy” rating and set a $92.00 price objective for the company in a research report on Wednesday, August 2nd. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Cantel Medical Corp. has a consensus rating of “Hold” and a consensus price target of $91.67.

Cantel Medical Corp. (NYSE:CMD) opened at 98.08 on Wednesday. The company has a 50-day moving average of $92.78 and a 200 day moving average of $80.29. Cantel Medical Corp. has a 52-week low of $68.19 and a 52-week high of $99.83. The company has a market cap of $4.07 billion, a PE ratio of 57.36 and a beta of 1.25.

Cantel Medical Corp. (NYSE:CMD) last issued its earnings results on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.52 by $0.02. Cantel Medical Corp. had a net margin of 9.27% and a return on equity of 17.60%. The firm had revenue of $205.50 million for the quarter, compared to analyst estimates of $200.32 million. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. Equities research analysts predict that Cantel Medical Corp. will post $2.34 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Cantel Medical Corp. (CMD) Short Interest Update” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/01/cantel-medical-corp-cmd-short-interest-update.html.

Cantel Medical Corp. Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.